Acinetobacter baumannii GC2 Sublineage Carrying the aac ( 6 ')- Im Amikacin, Netilmicin, and Tobramycin Resistance Gene Cassette.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Harmer CJ;Harmer CJ; Nigro SJ; Nigro SJ; Hall RM; Hall RM
  • Source:
    Microbiology spectrum [Microbiol Spectr] 2023 Aug 17; Vol. 11 (4), pp. e0120423. Date of Electronic Publication: 2023 Jul 06.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: ASM Press Country of Publication: United States NLM ID: 101634614 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2165-0497 (Electronic) Linking ISSN: 21650497 NLM ISO Abbreviation: Microbiol Spectr Subsets: MEDLINE
    • Publication Information:
      Original Publication: Washington, DC : ASM Press, 2013-
    • Subject Terms:
    • Abstract:
      The aminoglycoside antibiotics amikacin, gentamicin, and tobramycin are important therapeutic options for Acinetobacter iinfections. Several genes that confer resistance to one or more of these antibiotics are prevalent in the globally distributed resistant clones of Acinetobacter baumannii, but the aac ( 6 ')- Im ( aacA16 ) gene (amikacin, netilmicin, and tobramycin resistance), first reported in isolates from South Korea, has rarely been reported since. In this study, GC2 isolates (1999 to 2002) from Brisbane, Australia, carrying aac ( 6 ')- Im and belonging to the ST2:ST423:KL6:OCL1 type were identified and sequenced. The aac ( 6 ')- Im gene and surrounds have been incorporated into one end of the IS 26 -bounded AbGRI2 antibiotic resistance island and are accompanied by a characteristic 70.3-kbp deletion of adjacent chromosome. The compete genome of the 1999 isolate F46 (RBH46) includes only two copies of ISAba1 (in AbGRI1-3 and upstream of ampC ) but later isolates, which differ from one another by <10 single nucleotide differences (SND), carry two to seven additional shared copies. Several complete GC2 genomes with aac ( 6 ')- Im in an AbGRI2 island (2004 to 2017; several countries) found in GenBank and two additional Australian A. baumannii isolates (2006) carry different gene sets, KL2, KL9, KL40, or KL52, at the capsule locus. These genomes include ISAba1 copies in a different set of shared locations. The distribution of SND between F46 and AYP-A2, a 2013 ST2:ST208:KL2:OCL1 isolate from Victoria, Australia, revealed that a 640-kbp segment that includes KL2 and the AbGRI1 resistance island replaces the corresponding region in F46. Over 1,000 A. baumannii draft genomes also include aac ( 6 ')- Im , indicating that it is currently globally disseminated and significantly underreported. IMPORTANCE Aminoglycosides are important therapeutic options for treatment of Acinetobacter infections. Here, we show that a little-known aminoglycoside resistance gene, aac(6')-Im ( aacA16 ), that confers amikacin, netilmicin, and tobramycin resistance has been circulating undetected for many years in a sublineage of A. baumannii global clone 2 (GC2), generally with a second aminoglycoside resistance gene, aacC1 , which confers resistance to gentamicin. These two genes are commonly found together in GC2 complete and draft genomes and globally distributed. One isolate appears to be ancestral, as its genome contains few ISAba1 copies, providing insight into the original source of this insertion sequence (IS), which is abundant in most GC2 isolates. Tracking ISAba1 spread can provide a simple means to track the development and ongoing evolution as well as the dissemination of specific lineages and detect the formation of many sublineages. The complete ancestral genome will provide an essential base point for tracking this process.
      Competing Interests: The authors declare no conflict of interest.
    • References:
      J Antimicrob Chemother. 2012 Feb;67(2):335-8. (PMID: 22020138)
      J Antimicrob Chemother. 2019 Mar 1;74(3):821-823. (PMID: 30452642)
      Antimicrob Agents Chemother. 2001 Oct;45(10):2691-4. (PMID: 11557456)
      mSphere. 2016 Jun 08;1(3):. (PMID: 27303751)
      Genome Med. 2016 Mar 03;8(1):26. (PMID: 26939581)
      Microb Genom. 2020 Mar;6(3):. (PMID: 32118530)
      mBio. 2014 Oct 07;5(5):e01801-14. (PMID: 25293759)
      FEMS Microbiol Lett. 2011 Oct;323(1):44-51. (PMID: 22092679)
      J Antimicrob Chemother. 2012 Dec;67(12):2833-6. (PMID: 22888272)
      Microbiol Resour Announc. 2018 Dec 6;7(22):. (PMID: 30533856)
      ACS Chem Biol. 2013 Jan 18;8(1):105-15. (PMID: 23110460)
      J Appl Microbiol. 2021 Dec;131(6):2715-2738. (PMID: 33971055)
      Antimicrob Agents Chemother. 2004 Nov;48(11):4250-5. (PMID: 15504849)
      J Clin Microbiol. 2010 Nov;48(11):4051-6. (PMID: 20739495)
      J Antimicrob Chemother. 2014 Jun;69(6):1483-91. (PMID: 24486871)
      BMC Genomics. 2015 Sep 03;16:667. (PMID: 26336060)
      Microb Genom. 2019 Jan;5(1):. (PMID: 30648939)
      Int J Antimicrob Agents. 2008 Aug;32(2):165-9. (PMID: 18565738)
      Antimicrob Agents Chemother. 1998 Jun;42(6):1506-8. (PMID: 9624504)
      Sci Rep. 2016 Apr 13;6:24342. (PMID: 27072398)
      Clin Microbiol Rev. 2008 Jul;21(3):538-82. (PMID: 18625687)
      J Antimicrob Chemother. 2021 Mar 12;76(4):893-900. (PMID: 33452522)
      Bioinformatics. 2019 Feb 1;35(3):521-522. (PMID: 30016412)
      J Med Microbiol. 1998 May;47(5):455-62. (PMID: 9879947)
      Antimicrob Agents Chemother. 1998 Feb;42(2):483. (PMID: 9527817)
      Int J Antimicrob Agents. 2015 Nov;46(5):526-31. (PMID: 26362951)
      J Antimicrob Chemother. 2021 Feb 11;76(3):587-595. (PMID: 33338207)
      J Antimicrob Chemother. 2016 Sep;71(9):2432-40. (PMID: 27246238)
      Antimicrob Agents Chemother. 2015 Dec 14;60(3):1421-9. (PMID: 26666934)
      Microb Drug Resist. 2009 Sep;15(3):167-72. (PMID: 19728773)
      Infect Dis Clin North Am. 2016 Jun;30(2):523-537. (PMID: 27208771)
      PLoS Comput Biol. 2017 Jun 8;13(6):e1005595. (PMID: 28594827)
      FEMS Microbiol Rev. 2009 Jul;33(4):757-84. (PMID: 19416365)
      J Antimicrob Chemother. 2022 Mar 31;77(4):934-943. (PMID: 35084023)
      J Bacteriol. 2011 Nov;193(22):6393-4. (PMID: 22038960)
      J Antimicrob Chemother. 2017 Oct 1;72(10):2944-2947. (PMID: 28666372)
      J Antimicrob Chemother. 2017 Apr 1;72(4):1031-1039. (PMID: 28073968)
      mBio. 2014 Apr 22;5(2):e00915. (PMID: 24757213)
      J Clin Microbiol. 2017 Jul;55(7):2287-2289. (PMID: 28490493)
      Clin Infect Dis. 2007 Jul 1;45(1):88-94. (PMID: 17554708)
      PLoS One. 2013 Apr 16;8(4):e62160. (PMID: 23614028)
      Genome Res. 2015 Jul;25(7):1043-55. (PMID: 25977477)
      Microbiol Spectr. 2022 Oct 26;10(5):e0228722. (PMID: 36073931)
      mSphere. 2016 Apr 06;1(2):. (PMID: 27303727)
      Genome Announc. 2015 Mar 12;3(2):. (PMID: 25767221)
      J Antimicrob Chemother. 2013 Nov;68(11):2682-3. (PMID: 23788477)
      Microb Genom. 2016 Jul 18;2(7):e000062. (PMID: 28348858)
      J Antimicrob Chemother. 2013 Mar;68(3):554-7. (PMID: 23169892)
      PLoS One. 2017 May 1;12(5):e0176695. (PMID: 28459877)
      J Antimicrob Chemother. 2012 Dec;67(12):2825-32. (PMID: 22952140)
      J Antimicrob Chemother. 2018 Dec 1;73(12):3518-3520. (PMID: 30124881)
      Antimicrob Agents Chemother. 1997 Feb;41(2):314-8. (PMID: 9021185)
      FEMS Microbiol Rev. 2011 Sep;35(5):820-55. (PMID: 21564142)
      Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13758-63. (PMID: 21825119)
      Carbohydr Res. 2015 May 29;409:30-5. (PMID: 25917131)
      Microb Genom. 2018 Mar;4(3):. (PMID: 29547094)
      J Med Microbiol. 2011 Apr;60(Pt 4):515-521. (PMID: 21163830)
      J Antimicrob Chemother. 2011 Jul;66(7):1504-9. (PMID: 21586593)
      Microb Genom. 2016 Feb 23;2(2):e000052. (PMID: 28348844)
      Drug Resist Updat. 2018 Nov;41:26-39. (PMID: 30472242)
    • Contributed Indexing:
      Keywords: Acinetobacter baumannii evolution; aac(6′)-Im; aminoglycoside resistance; antibiotic resistance; capsule locus; genomic island; global clone 1; insertion sequence; insertion sequence ISAba1
    • Accession Number:
      84319SGC3C (Amikacin)
      4O5J85GJJB (Netilmicin)
      VZ8RRZ51VK (Tobramycin)
      0 (Interleukin-1 Receptor-Like 1 Protein)
      0 (Anti-Bacterial Agents)
      0 (Aminoglycosides)
      0 (Gentamicins)
    • Publication Date:
      Date Created: 20230706 Date Completed: 20230821 Latest Revision: 20230830
    • Publication Date:
      20230830
    • Accession Number:
      PMC10434200
    • Accession Number:
      10.1128/spectrum.01204-23
    • Accession Number:
      37409961